Catecholamine-induced muscle weakness.
Infusions of epinephrine or levarterenol bitartrate into a rabbit nerve-muscle preparation decreased the force of the evoked twitch of anterior tibial and gastrocnemius-soleus muscles. The adverse effect of the catecholamines was not directly on skeletal muscle. The alpha-receptor blocking drug phenoxybenzamine hydrochloride prevented the adverse effect of the catecholamines if it was given prior to catecholamine infusions and unmasked a weak augmentation of twitch tension. Taken with the finding of abnormal accumulation of catecholamine in human dystrophic muscles, the production of an experimental myopathy resembling human dystrophy by the monoamine oxidase inhibitor pargyline hydrochloride, and the finding of excessive levels of catecholamines in the tissues and urine of dystrophic animals, these experiments support the hypothesis that catecholamines could play a pathogenetic role in some dystrophic diseases of muscle.
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002038:Bungarotoxins / Q000494:pharmacology; D002395:Catecholamines / Q000494:pharmacology*; D004347:Drug Interactions; D004558:Electric Stimulation; D004837:Epinephrine / Q000494:pharmacology; D006614:Hindlimb; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009469:Neuromuscular Junction / Q000187:drug effects* / Q000502:physiology; D009638:Norepinephrine / Q000031:analogs & derivatives / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011817:Rabbits; D012584:Sciatic Nerve / Q000187:drug effects / Q000502:physiology; D013997:Time Factors
D002038:Bungarotoxins; D002395:Catecholamines; D010643:Phenoxybenzamine; D011433:Propranolol; D009638:Norepinephrine; D004837:Epinephrine